Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Malaria Journal
Published in: Malaria Journal 1/2013

Open Access 01-12-2013 | Case study

Ivermectin to reduce malaria transmission: a research agenda for a promising new tool for elimination

Authors: Carlos J Chaccour, Kevin C Kobylinski, Quique Bassat, Teun Bousema, Chris Drakeley, Pedro Alonso, Brian D Foy

Published in: Malaria Journal | Issue 1/2013

Login to get access

Abstract

Background

The heterogeneity of malaria transmission makes widespread elimination a difficult goal to achieve. Most of the current vector control measures insufficiently target outdoor transmission. Also, insecticide resistance threatens to diminish the efficacy of the most prevalent measures, indoor residual spray and insecticide treated nets. Innovative approaches are needed. The use of endectocides, such as ivermectin, could be an important new addition to the toolbox of anti-malarial measures. Ivermectin effectively targets outdoor transmission, has a novel mechanism of action that could circumvent resistance and might be distributed over the channels already in place for the control of onchocerciasis and lymphatic filariasis.

Methods

The previous works involving ivermectin and Anopheles vectors are reviewed and summarized. A review of ivermectin’s safety profile is also provided. Finally three definitive clinical trials are described in detail and proposed as the evidence needed for implementation. Several smaller and specific supportive studies are also proposed.

Conclusions

The use of ivermectin solves many challenges identified for future vector control strategies. It is an effective and safe endectocide that was approved for human use more than 25 years ago. Recent studies suggest it might become an effective and complementary strategy in malaria elimination and eradication efforts; however, intensive research will be needed to make this a reality.
Literature
1.
Alonso PL, Brown G, Arevalo-Herrera M, Binka F, Chitnis C, Collins F, Doumbo OK, Greenwood B, Hall BF, Levine MM, Mendis K, Newman RD, Plowe CV, Rodriguez MH, Sinden R, Slutsker L, Tanner M: A research agenda to underpin malaria eradication. PLoS Med. 2011, 8: e1000406. 10.1371/journal.pmed.1000406.PubMedCentralCrossRefPubMed
2.
Greenwood BM, Fidock DA, Kyle DE, Kappe SH, Alonso PL, Collins FH, Duffy PE: Malaria: progress, perils, and prospects for eradication. J Clin Invest. 2008, 118: 1266-1276. 10.1172/JCI33996.PubMedCentralCrossRefPubMed
3.
Djogbenou L, Labbe P, Chandre F, Pasteur N, Weill M: Ace-1 duplication in Anopheles gambiae: a challenge for malaria control. Malar J. 2009, 8: 70. 10.1186/1475-2875-8-70.PubMedCentralCrossRefPubMed
4.
Ranson H, N’Guessan R, Lines J, Moiroux N, Nkuni Z, Corbel V: Pyrethroid resistance in African anopheline mosquitoes: what are the implications for malaria control?. Trends Parasitol. 2011, 27: 91-98. 10.1016/j.pt.2010.08.004.CrossRefPubMed
5.
Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, Lwin KM, Ariey F, Hanpithakpong W, Lee SJ, Ringwald P, Silamut K, Imwong M, Chotivanich K, Lim P, Herdman T, An SS, Yeung S, Singhasivanon P, Day NP, Lindegardh N, Socheat D, White NJ: Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2009, 361: 455-467. 10.1056/NEJMoa0808859.PubMedCentralCrossRefPubMed
6.
Dondorp AM, Yeung S, White L, Nguon C, Day NP, Socheat D, von Seidlein L: Artemisinin resistance: current status and scenarios for containment. Nat Rev Microbiol. 2010, 8: 272-280.CrossRefPubMed
7.
8.
Cotter C, Sturrock HJ, Hsiang MS, Liu J, Phillips AA, Hwang J, Gueye CS, Fullman N, Gosling RD, Feachem RG: The changing epidemiology of malaria elimination: new strategies for new challenges. Lancet. 2013, in press
9.
The malERA Consultative Group on Vector Control: A research agenda for malaria eradication: vector control. PLoS Med. 2011, 8: e1000401.PubMedCentralCrossRef
10.
Edi CV, Koudou BG, Jones CM, Weetman D, Ranson H: Multiple-insecticide resistance in Anopheles gambiae mosquitoes, Southern Cote d’Ivoire. Emerg Infect Dis. 2012, 18: 1508-1511. 10.3201/eid1809.120262.PubMedCentralCrossRefPubMed
11.
Govella NJ, Ferguson H: Why use of interventions targeting outdoor biting mosquitoes will be necessary to achieve malaria elimination. Front Physiol. 2012, 3: 199.PubMedCentralCrossRefPubMed
12.
Kelly-Hope LA, McKenzie FE: The multiplicity of malaria transmission: a review of entomological inoculation rate measurements and methods across sub-Saharan Africa. Malar J. 2009, 8: 19. 10.1186/1475-2875-8-19.PubMedCentralCrossRefPubMed
13.
14.
Fox LM: Ivermectin: uses and impact 20 years on. Curr Opin Infect Dis. 2006, 19: 588-593. 10.1097/QCO.0b013e328010774c.CrossRefPubMed
15.
16.
Kobylinski KC, Deus KM, Butters MP, Hongyu T, Gray M, da Silva IM, Sylla M, Foy BD: The effect of oral anthelmintics on the survivorship and re-feeding frequency of anthropophilic mosquito disease vectors. Acta Trop. 2010, 116: 119-126. 10.1016/j.actatropica.2010.06.001.PubMedCentralCrossRefPubMed
17.
Tesh RB, Guzman H: Mortality and infertility in adult mosquitoes after the ingestion of blood containing ivermectin. AmJTrop Med Hyg. 1990, 43: 229-233.
18.
Wilson ML: Avermectins in arthropod vector management - prospects and pitfalls. Parasitol Today. 1993, 9: 83-87. 10.1016/0169-4758(93)90210-7.CrossRefPubMed
19.
Chaccour C, Lines J, Whitty CJ: Effect of ivermectin on Anopheles gambiae mosquitoes fed on humans: the potential of oral insecticides in malaria control. J Infect Dis. 2010, 202: 113-116. 10.1086/653208.CrossRefPubMed
20.
Foley DH, Bryan JH, Lawrence GW: The potential of ivermectin to control the malaria vector Anopheles farauti. Trans R Soc Trop Med Hyg. 2000, 94: 625-628. 10.1016/S0035-9203(00)90211-6.CrossRefPubMed
21.
Bockarie MJ, Hii JL, Alexander ND, Bockarie F, Dagoro H, Kazura JW, Alpers MP: Mass treatment with ivermectin for filariasis control in Papua New Guinea: impact on mosquito survival. Med Vet Entomol. 1999, 13: 120-123. 10.1046/j.1365-2915.1999.00159.x.CrossRefPubMed
22.
Kobylinski KC, Sylla M, Chapman PL, Sarr MD, Foy BD: Ivermectin mass drug administration to humans disrupts malaria parasite transmission in Senegalese villages. AmJTrop Med Hyg. 2011, 85: 3-5. 10.4269/ajtmh.2011.11-0160.CrossRef
23.
Sylla M, Kobylinski KC, Gray M, Chapman PL, Sarr MD, Rasgon JL, Foy BD: Mass drug administration of ivermectin in south-eastern Senegal reduces the survivorship of wild-caught, blood fed malaria vectors. Malar J. 2010, 9: 365. 10.1186/1475-2875-9-365.PubMedCentralCrossRefPubMed
24.
Pampiglione S, Majori G, Petrangeli G, Romi R: Avermectins, MK-933 and MK-936, for mosquito control. Trans R Soc Trop Med Hyg. 1985, 79: 797-799. 10.1016/0035-9203(85)90121-X.CrossRefPubMed
25.
Iakubovich V, Zakharova NF, Alekseev AN, Alekseev EA: Evaluation of the action of ivermectin on blood-sucking mosquitoes. Med Parazitol (Mosk). 1989, 3: 60-64.
26.
Jones JW, Meisch MV, Meek CL, Bivin WS: Lethal effects of ivermectin on Anopheles quadrimaculatus. J Am Mosq Control Assoc. 1992, 8: 278-280.PubMed
27.
Gardner K, Meisch MV, Meek CL, Biven WS: Effects of ivermectin in canine blood on Anopheles quadrimaculatus, Aedes albopictus and Culex salinarius. J Am Mosq Control Assoc. 1993, 9: 400-402.PubMed
28.
Fritz ML, Siegert PY, Walker ED, Bayoh MN, Vulule JR, Miller JR: Toxicity of bloodmeals from ivermectin-treated cattle to Anopheles gambiae s.l. Ann Trop Med Parasitol. 2009, 103: 539-547. 10.1179/000349809X12459740922138.CrossRefPubMed
29.
Butters MP, Kobylinski KC, Deus KM, da Silva IM, Gray M, Sylla M, Foy BD: Comparative evaluation of systemic drugs for their effects against Anopheles gambiae. Acta Trop. 2012, 121: 34-43. 10.1016/j.actatropica.2011.10.007.PubMedCentralCrossRefPubMed
30.
Fritz ML, Walker ED, Miller JR: Lethal and sublethal effects of avermectin/milbemycin parasiticides on the African malaria vector, Anopheles arabiensis. J Med Entomol. 2012, 49: 326-331. 10.1603/ME11098.CrossRefPubMed
31.
Hooghof J, Lindsay SW, Drakeley C, Churcher T, Verhave JP, Kocken C, Sauerwein RW, Bousema T, Bastiaens G vGG: Duration of the mosquitocidal effect of ivermectin. MW Journal. 2012, 3: 1-5.
32.
Kobylinski KC, Foy BD, Richardson JH: Ivermectin inhibits the sporogony of Plasmodium falciparum in Anopheles gambiae. Malar J. 2012, 11: 381. 10.1186/1475-2875-11-381.PubMedCentralCrossRefPubMed
33.
Garrett-Jones C, Shidrawi GR: Malaria vectorial capacity of a population of Anopheles gambiae: an exercise in epidemiological entomology. Bull World Health Organ. 1969, 40: 531-545.PubMedCentralPubMed
34.
Macdonald G: The analysis of equilibrium in malaria. Trop Dis Bull. 1952, 49: 813-829.PubMed
35.
Foy BD, Kobylinski KC, da Silva IM, Rasgon JL, Sylla M: Endectocides for malaria control. Trends Parasitol. 2011, 27: 423-428. 10.1016/j.pt.2011.05.007.PubMedCentralCrossRefPubMed
36.
Mackenzie CD, Geary TG, Gerlach JA: Possible pathogenic pathways in the adverse clinical events seen following ivermectin administration to onchocerciasis patients. Filaria J. 2003, 2 (1): S5. 10.1186/1475-2883-2-5.PubMedCentralCrossRefPubMed
37.
Njoo FL, Beek WM, Keukens HJ, van Wilgenburg H, Oosting J, Stilma JS, Kijlstra A: Ivermectin detection in serum of onchocerciasis patients: relationship to adverse reactions. AmJTrop Med Hyg. 1995, 52: 94-97.
38.
Gardon J, Gardon-Wendel N, Demanga N, Kamgno J, Chippaux JP, Boussinesq M: Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for Loa loa infection. Lancet. 1997, 350: 18-22. 10.1016/S0140-6736(96)11094-1.CrossRefPubMed
39.
Wanji S, Akotshi DO, Mutro MN, Tepage F, Ukety TO, Diggle PJ, Remme JH: Validation of the rapid assessment procedure for loiasis (RAPLOA) in the democratic republic of Congo. Parasit Vectors. 2012, 5: 25. 10.1186/1756-3305-5-25.PubMedCentralCrossRefPubMed
40.
Duke BO, Pacque MC, Munoz B, Greene BM, Taylor HR: Viability of adult Onchocerca volvulus after six 2-weekly doses of ivermectin. Bull World Health Organ. 1991, 69: 163-168.PubMedCentralPubMed
41.
Awadzi K, Opoku NO, Addy ET, Quartey BT: The chemotherapy of onchocerciasis. XIX: The clinical and laboratory tolerance of high dose ivermectin. Trop Med Parasitol. 1995, 46: 131-137.PubMed
42.
Guzzo CA, Furtek CI, Porras AG, Chen C, Tipping R, Clineschmidt CM, Sciberras DG, Hsieh JY, Lasseter KC: Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects. J Clin Pharmacol. 2002, 42: 1122-1133. 10.1177/009127002401382731.CrossRefPubMed
43.
Kamgno J, Gardon J, Gardon-Wendel N, Demanga N, Duke BO, Boussinesq M: Adverse systemic reactions to treatment of onchocerciasis with ivermectin at normal and high doses given annually or three-monthly. Trans R Soc Trop Med Hyg. 2004, 98: 496-504. 10.1016/j.trstmh.2003.10.018.CrossRefPubMed
44.
45.
Pacque M, Munoz B, Poetschke G, Foose J, Greene BM, Taylor HR: Pregnancy outcome after inadvertent ivermectin treatment during community-based distribution. Lancet. 1990, 336: 1486-1489. 10.1016/0140-6736(90)93187-T.CrossRefPubMed
46.
Chippaux JP, Gardon-Wendel N, Gardon J, Ernould JC: Absence of any adverse effect of inadvertent ivermectin treatment during pregnancy. Trans R Soc Trop Med Hyg. 1993, 87: 318. 10.1016/0035-9203(93)90146-H.CrossRefPubMed
47.
Doumbo O, Soula G, Kodio B, Perrenoud M: Ivermectin and pregnancy in mass treatment in Mali. Bull Soc Pathol Exot. 1992, 85: 247-251.PubMed
48.
Gyapong JO, Chinbuah MA, Gyapong M: Inadvertent exposure of pregnant women to ivermectin and albendazole during mass drug administration for lymphatic filariasis. Trop Med Int Health. 2003, 8: 1093-1101. 10.1046/j.1360-2276.2003.01142.x.CrossRefPubMed
49.
Ndyomugyenyi R, Kabatereine N, Olsen A, Magnussen P: Efficacy of ivermectin and albendazole alone and in combination for treatment of soil-transmitted helminths in pregnancy and adverse events: a randomized open label controlled intervention trial in Masindi district, western Uganda. AmJTrop Med Hyg. 2008, 79: 856-863.
50.
Brown KR: Changes in the use profile of Mectizan: 1987–1997. Ann Trop Med Parasitol. 1998, 92 (Suppl 1): S61-64.CrossRefPubMed
51.
Ogbuokiri JE, Ozumba BC, Okonkwo PO: Ivermectin levels in human breastmilk. Eur J Clin Pharmacol. 1993, 45: 389-390.CrossRefPubMed
52.
Gutman J, Emukah E, Okpala N, Okoro C, Obasi A, Miri ES, Richards FO: Effects of annual mass treatment with ivermectin for onchocerciasis on the prevalence of intestinal helminths. AmJTrop Med Hyg. 2010, 83: 534-541. 10.4269/ajtmh.2010.10-0033.CrossRef
53.
Bousema JT, Schneider P, Gouagna LC, Drakeley CJ, Tostmann A, Houben R, Githure JI, Ord R, Sutherland CJ, Omar SA, Sauerwein RW: Moderate effect of artemisinin-based combination therapy on transmission of Plasmodium falciparum. J Infect Dis. 2006, 193: 1151-1159. 10.1086/503051.CrossRefPubMed
54.
Sutherland CJ, Ord R, Dunyo S, Jawara M, Drakeley CJ, Alexander N, Coleman R, Pinder M, Walraven G, Targett GA: Reduction of malaria transmission to Anopheles mosquitoes with a six-dose regimen of co-artemether. PLoS Med. 2005, 2: e92. 10.1371/journal.pmed.0020092.PubMedCentralCrossRefPubMed
55.
Okell LC, Griffin JT, Kleinschmidt I, Hollingsworth TD, Churcher TS, White MJ, Bousema T, Drakeley CJ, Ghani AC: The potential contribution of mass treatment to the control of Plasmodium falciparum malaria. PLoS One. 2011, 6: e20179. 10.1371/journal.pone.0020179.PubMedCentralCrossRefPubMed
56.
von Seidlein L, Greenwood BM: Mass administrations of antimalarial drugs. Trends Parasitol. 2003, 19: 452-460. 10.1016/j.pt.2003.08.003.CrossRefPubMed
57.
58.
Baird JK, Surjadjaja C: Consideration of ethics in primaquine therapy against malaria transmission. Trends Parasitol. 2011, 27: 11-16. 10.1016/j.pt.2010.08.005.CrossRefPubMed
59.
Brosseau L, Drame PM, Besnard P, Toto JC, Foumane V, Le Mire J, Mouchet F, Remoue F, Allan R, Fortes F, Carnevale P, Manguin S: Human antibody response to Anopheles saliva for comparing the efficacy of three malaria vector control methods in Balombo. Angola. PLoS One. 2012, 7: e44189. 10.1371/journal.pone.0044189.CrossRefPubMed
60.
Stone W, Bousema T, Jones S, Gesase S, Hashim R, Gosling R, Carneiro I, Chandramohan D, Theander T, Ronca R, Modiano D, Arca B, Drakeley C: IgG responses to Anopheles gambiae salivary antigen gSG6 detect variation in exposure to malaria vectors and disease risk. PLoS One. 2012, 7: e40170. 10.1371/journal.pone.0040170.PubMedCentralCrossRefPubMed
61.
Stevenson J, St Laurent B, Lobo NF, Cooke MK, Kahindi SC, Oriango RM, Harbach RE, Cox J, Drakeley C: Novel vectors of malaria parasites in the western highlands of Kenya. Emerg Infect Dis. 2012, 18: 1547-1549. 10.3201/eid1809.120283.PubMedCentralCrossRefPubMed
62.
Osei-Atweneboana MY, Awadzi K, Attah SK, Boakye DA, Gyapong JO, Prichard RK: Phenotypic evidence of emerging ivermectin resistance in Onchocerca volvulus. PLoS Negl Trop Dis. 2011, 5: e998. 10.1371/journal.pntd.0000998.PubMedCentralCrossRefPubMed
Metadata
Title
Ivermectin to reduce malaria transmission: a research agenda for a promising new tool for elimination
Authors
Carlos J Chaccour
Kevin C Kobylinski
Quique Bassat
Teun Bousema
Chris Drakeley
Pedro Alonso
Brian D Foy
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Malaria Journal / Issue 1/2013
Electronic ISSN: 1475-2875
DOI
https://doi.org/10.1186/1475-2875-12-153

Other articles of this Issue 1/2013

Malaria Journal 1/2013 Go to the issue

Methodology

Barrier screens: a method to sample blood-fed and host-seeking exophilic mosquitoes

Research

Netting barriers to prevent mosquito entry into houses in southern Mozambique: a pilot study

Research

Comparative evaluation of published real-time PCR assays for the detection of malaria following MIQE guidelines

Research

Inland valley rice production systems and malaria infection and disease in the forest region of western Côte d’Ivoire

Research

Seroepidemiological and parasitological evaluation of the heterogeneity of malaria infection in the Gambia

Research

Dose–response tests and semi-field evaluation of lethal and sub-lethal effects of slow release pyriproxyfen granules (Sumilarv®0.5G) for the control of the malaria vectors Anopheles gambiae sensu lato
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits